Five years on from the start of the pandemic, with its worldwide lockdowns and border closures, new data has revealed a way ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.

The New Hampshire Department of Health and Human Services (DHHS) said a person from Merrimack County has become the first ...

The Penn Center for Innovation has enabled world-changing advancements, from mRNA vaccines to CAR T cancer treatments.

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

University of Wisconsin Health reported the highest rate of hospitalizations for influenza in the past three years last week, ...

A new study analyzing long COVID health care utilization in Colorado reveals a significant shift from acute care to ...

Children with COVID-19 vs RSV or influenza infections are at an increased risk of developing cardiovascular complications.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Compared with placebo, fostamatinib did not increase the number of oxygen-free days among adults hospitalized with COVID-19 and hypoxemia.

Separately, the FDA has linked ready-to-eat mini pastries imported from Canada with a salmonella outbreak that has sickened 18 in the U.S. Other outbreak news is on mpox, measles, flu, covid, ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...